PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
16.31%
Revenue growth above 1.5x AVGO's 6.80%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
149.98%
Gross profit growth above 1.5x AVGO's 12.88%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
197.95%
EBIT growth above 1.5x AVGO's 25.00%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
197.95%
Operating income growth above 1.5x AVGO's 25.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
202.16%
Net income growth above 1.5x AVGO's 36.67%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
204.17%
EPS growth above 1.5x AVGO's 34.21%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
200.00%
Diluted EPS growth above 1.5x AVGO's 35.14%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.85%
Share count expansion well above AVGO's 0.42%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.08%
Diluted share count expanding well above AVGO's 0.41%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
4.59%
OCF growth under 50% of AVGO's 19.13%. Michael Burry might suspect questionable revenue recognition or rising costs.
6.18%
FCF growth under 50% of AVGO's 18.56%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
496.50%
10Y revenue/share CAGR above 1.5x AVGO's 12.18%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
58.28%
5Y revenue/share CAGR above 1.5x AVGO's 12.18%. David Dodd would look for consistent product or market expansions fueling outperformance.
5.57%
3Y revenue/share CAGR under 50% of AVGO's 12.18%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
762.18%
10Y OCF/share CAGR above 1.5x AVGO's 104.45%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
29321.27%
5Y OCF/share CAGR above 1.5x AVGO's 104.45%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-53.15%
Negative 3Y OCF/share CAGR while AVGO stands at 104.45%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
550.14%
Net income/share CAGR above 1.5x AVGO's 150.30% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
275.60%
5Y net income/share CAGR above 1.5x AVGO's 150.30%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-3.13%
Negative 3Y CAGR while AVGO is 150.30%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1477.85%
Equity/share CAGR of 1477.85% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
97.57%
Equity/share CAGR of 97.57% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
25.94%
Equity/share CAGR of 25.94% while AVGO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.03%
AR growth well above AVGO's 12.05%. Michael Burry fears inflated revenue or higher default risk in the near future.
-0.56%
Inventory is declining while AVGO stands at 3.93%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
5.01%
Asset growth at 50-75% of AVGO's 7.74%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
6.93%
50-75% of AVGO's 10.62%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-1.20%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
2.64%
R&D growth drastically higher vs. AVGO's 1.43%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
16.24%
SG&A growth well above AVGO's 6.25%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.